Supriya Lifescience Ltd
Supriya Lifescience Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #26 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Supriya Lifescience aims for ~20% annual revenue growth, with stronger traction expected in H2 FY '26 after a muted H1 due to plant debottlenecking. Supriya Lifescience targets around 20% annual revenue growth, expected to be driven by recovery post-Q1 shutdown, new product launches, and CMO/CDMO partnerships.
From Supriya Lifescience Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Supriya Lifescience aims for ~20% annual revenue growth, with stronger traction expected in H2 FY '26 after a muted H1 due to plant debottlenecking.
- New product launches (4 planned in FY '26 including anesthetic, cardiovascular intermediate, ADHD, and contrast media) will drive growth.
- Ambernath facility to start contributing from Q4 FY '26; full impact expected over 2-3 years for finished formulations and CDMO business.
- Advanced cardiovascular intermediate capacity set at 1,000 tons, with initial visibility of ~300 tons, scaling up in coming quarters.
- GLP-1 finished formulation expected to generate revenue from next financial year, focusing on non-patented markets.
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ambernath facility: Major ongoing CAPEX, progressing well; expected to start contributing revenue from Q4 FY '26.
- Full-year CAPEX guidance: INR 80-90 crores for FY '26.
- H1 FY '26 CAPEX: INR 42 crores mainly towards Ambernath facility.
- H2 FY '26 CAPEX: Primarily maintenance CAPEX, Ribo Block at Lote site, and other small projects related to formulations plant.
- Module E optimization: Majority already capitalized; minor remaining capitalization ongoing.
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- For the cardiovascular advanced intermediate, Supriya Lifescience has visibility of about 300 tons of orders and is in advanced discussions with customers.
- For the anesthetic product, customers are currently taking APIs for validations, indicating early-stage orders, with full revenue impact expected over 2 years.
- The Ambernath facility is expected to start contributing revenue from Q4 FY '26, with good order book already seen for liquid anesthetics and tablets in semi-regulated markets.
- The finished formulation segment is in initial partnership discussions; concrete order commitments are yet to be announced.
- The DSM partnership is expected to provide INR 25-30 crores of revenue in the current year from food applications, with full pharma customer qualification expected next year to reach INR 60 crores.
2 more points from Supriya Lifescience Ltd's call on order book
Create a free account to keep reading this call
Supriya Lifescience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹277 Cr, net profit ₹74 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifescience Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Supriya Lifescience Ltd Q2 FY26 results?
Supriya Lifescience aims for ~20% annual revenue growth, with stronger traction expected in H2 FY '26 after a muted H1 due to plant debottlenecking. Supriya Lifescience targets around 20% annual revenue growth, expected to be driven by recovery post-Q1 shutdown, new product launches, and CMO/CDMO partnerships.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a neutral. The stock trades at a P/E of 35.9 with a market cap of ₹7,128 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
Ambernath facility: Major ongoing CAPEX, progressing well; expected to start contributing revenue from Q4 FY '26.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.